Patients experienced a median weight loss of 10.5 kg after 12 months of GLP1-RA treatment for weight regain following .
Forty patients, predominantly female (80%), were analyzed for weight regain treatment.
, liraglutide and semaglutide, were initiated after a median of 74.5 months post-surgery following a weight regain of 14.7%.
The treatment resulted in a reduction of BMI by 3.7 kg/m and a percentage of excess body weight loss of 41.7%, equating to 99.3% of the regained weight.
A significant difference in BMI reduction was observed, with liraglutide showing a lower reduction compared to semaglutide (3.1 kg/m vs. 4.7 kg/m).
Adverse events occurred in 32.5% of patients, but all were mild and transient.
Simplified
BACKGROUND: The role of glucagon-like peptide-1 receptor agonists () in patients with weight regain after remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatment in a real-world patient population with weight regain after bariatric surgery.
METHODS: A single-centre retrospective observational study. Patients with post-bariatric weight regain subsequently treated with GLP1-RA were identified, and the effect on weight after 12 months of treatment was determined. Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively.
RESULTS: Forty patients (80% female) were included in the analysis. Liraglutide (3.0 mg, daily subcutaneous injection, n = 22) or semaglutide (1.0 mg, weekly subcutaneous injection, n = 18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%. After 12 months of GLP1-RA treatment, a total body weight, BMI, and percentage excess body weight reduction of 10.5 (6.1, 14.7) kg, 3.7 (2.5, 5.3) kg/m, and 41.7 (22.1, 70.5)% were observed, corresponding to a loss of 99.3 (61.0, 135.4)% of the weight regained (P-value < 0.0001). The observed reduction in BMI was significantly lower with liraglutide than with semaglutide, 3.1 (2.0, 4.7) vs. 4.7 (3.7, 6.0) kg/m(P-value = 0.04). Adverse events were reported in 13 (32.5%) patients, all of which were mild and transient. 2 2
CONCLUSION: GLP1-RA therapy with liraglutide or semaglutide for 12 months is efficacious and safe for the treatment of weight regain following bariatric surgery.
CLINICAL TRIAL NUMBER: Not applicable.
Key numbers
10.5 kg
Weight Loss Achieved
Median total body weight loss after 12 months of treatment.
99.3%
Percentage of Regained Weight Lost
Percentage of previously regained weight lost after treatment.
4.7 kg/m
Reduction with
Median reduction after 12 months of treatment with .
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: The regional ethics committee (EKOS Ethikkommission Ostschweiz, St. Gallen) approved the study (BASEC No. 2022 − 00208), and all participating patients had signed an informed general consent form. Consent for publication: Not applicable. Competing interests: Anders B Jensen is a previous employee (2008-2010) of Novo Nordisk A/S. None of the other coauthors have any competing interests to declare.
